Live Breaking News & Updates on Kalvista Pharmaceuticals Company Profile Get Rating

Equities analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) to report earnings per share of ($1.01) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for KalVista Pharmaceuticals’ earnings, with estimates ranging from ($1.19) to ($0.81). KalVista Pharmaceuticals posted earnings per share of ($0.65) during the same quarter last […] ....

Thomas Andrew Crockett , Securities Exchange Commission , Life Insurance Co , Zacks Investment Research , Capital Partners , Kalvista Pharmaceuticals Company Profile Get Rating , Needham Company , Kalvista Pharmaceuticals Inc , Jpmorgan Chase Co , Kalvista Pharmaceuticals , Royal Bank , Get Rating , Kalvista Pharmaceutical , Vista Pharmaceuticals , Investment Research , Roth Capital , Andrew Crockett , Exchange Commission , Vista Pharmaceuticals Company Profile , Nasdaq Kalv ,